Updates are available Erratum dated 2018-02-14
Click to view Erratum: https://doi.org/10.1038/nature25498
-
Authors
Saito, Fumiji
Hirayasu, Kouyuki
Satoh, Takeshi
Wang, Christian W.
Lusingu, John
Arimori, Takao
Shida, Kyoko
Palacpac, Nirianne Marie Q.
Itagaki, Sawako
Iwanaga, Shiroh
Takashima, Eizo
Tsuboi, Takafumi
Kohyama, Masako
Suenaga, Tadahiro
Colonna, Marco
Takagi, Junichi
Lavstsen, Thomas
Horii, Toshihiro
Arase, Hisashi
- License Information
-
More Information
Article History
Received: 9 March 2017
Accepted: 2 November 2017
First Online: 29 November 2017
Change Date: 14 February 2018
Change Type: Correction
Change Details: Change history: Please see accompanying Corrigendum (ExternalRef removed). In Extended Data Fig. 1, the flow cytometry panel showing uninfected erythrocytes stained with LILRB5-Fc was inadvertently duplicated
Competing interests
: Competing financial interests: Osaka university has filed a provisional patent application that covers the use of LILRB1-binding RIFINs as a possible target for malaria vaccine. F.S., K.H. and H.A. are listed as inventors.
